Good news! Humanwell's anxiety medicine, with an annual sales volume of nearly US $100 million, has been approved in the United States

On April 17, humanwell pharmaceutical announced that the buspirone hydrochloride tablets of its wholly-owned subsidiary epic Pharma, LLC (hereinafter referred to as epic Pharma) have passed anda (brief application for new drugs in the United States, i.e application for generic drugs in the United States) in the United States and can be produced and marketed Buspirone hydrochloride tablets are mainly used in the treatment of generalized anxiety disorder and other anxiety disorders Epicpharma submitted an anda application for buspirone hydrochloride tablets in 2016, with a cumulative R & D investment of about US $1 million According to IMS data statistics, the total sales volume of buspirone hydrochloride tablets in the U.S market in the last 12 months is about 88 million US dollars, and the main manufacturers include Teva, accordhealthcare, mylan, etc According to the data statistics of minenet, in 2017, the sales volume of buspirone tablets in the three terminal public hospitals of cities, counties and towns in China was about 130 million yuan, and the main manufacturers included Jiangsu Enhua Pharmaceutical Co., Ltd., Beijing HuaSu Pharmaceutical Co., Ltd and Peking University Pharmaceutical Co., Ltd Humanwell said that the FDA approval number of this buspirone hydrochloride tablet indicates that epicpharma has the qualification to sell the product in the U.S market, which will have a positive impact on the company's expansion of the U.S generic drug market, and the company will actively promote the preparation of the product's listing in the U.S market in the future.